42 results about "Intestinal Disorder" patented technology

The invention belongs to the technical field of biology, and discloses a reagent combination or kit for constructing intestinal organs and application of the reagent combination or kit. According to the reagent combination or the kit, intestinal organs can be obtained from cell-derived epithelial cells obtained from a donor in a non-invasive manner, and the obtained intestinal organs can be cryopreserved and recovered and can be amplified in vitro for a long time; transcriptome characteristics are similar to those of real human small intestine tissues, and typical marker genes of various small intestine pedigree cell types are highly expressed; compared with intestinal organs obtained through induction of pluripotent stem cells, the intestinal organs have more intestinal pedigree characteristics, and the intestinal function development is more mature; after being promoted to be mature, the intestinal organ also highly expresses genes related to drug absorption and metabolism, has drug absorption capability similar to that of an immortalized intestinal cell line, but more prominently shows intestinal cell lineage characteristics, is closer to an intestinal environment in a real human body, and can be used for screening intestinal disease drugs; the intestinal barrier function is realized.

The disclosure relates to a mixture of bacteria belonging to at least six or seven different and specific bacterial species preferably for use in preventing or treating gastro-intestinal disorders. Preferably, the mixture of bacteria is grown together in a fermenter prior to administering the mixture to a subject in order to prevent or treat the disorder.

A strain of Enterococcus faecalis, a composite bacterial agent, and application thereof, which relates to the field of microbiology. The Enterococcus faecalis strain was deposited on Oct. 13, 2022, at the Guangdong Microbial Culture Collection Center (GDMCC) with the deposit number GDMCC No. 62869. Both the Enterococcus faecalis strain and the composite bacterial agent can effectively treat intestinal disorders and inflammatory bowel disease in felines and can be used in the preparation of related pharmaceuticals.

The invention discloses an intestinal polyp identification method based on images and multi-modal data. The method comprises the following steps: acquiring pathological images of a plurality of microscopes, objective magnification information corresponding to the pathological images, and text information corresponding to enteroscopes; performing data preprocessing on each frame of acquired pathological image and text information to obtain a training data set; a multi-scale multi-modal feature classification network is constructed, the training data set is used for training, and a trained multi-scale multi-modal feature fusion classification network is obtained; the method comprises the following steps: collecting a microscope pathological image of a patient, obtaining corresponding enteroscope text information, respectively carrying out data preprocessing, and inputting into a multi-scale multi-modal feature fusion classification network to obtain disease category prediction of a model. According to the method, pathological images and enteroscope text information are fully fused, accurate classification and prediction of disease types are finally achieved, the effect and efficiency of multi-modal diagnosis of intestinal diseases are improved, and therefore the accuracy of patient diagnosis is improved.

The invention belongs to the technical field of microorganisms, and discloses a heat-resistant and acid-base-resistant clostridium perfringens bacteriophage XHX-CP-18P and application thereof, the bacteriophage is preserved in the China Center for Type Culture Collection (CCTCC) on March 17, 2025, and the preservation number is CCTCC NO: M 2025492. The invention also provides a bactericide product prepared from the bacteriophage. The bacteriophage has good acid and alkali resistance under the condition that the pH is 3-13, has heat resistance under the condition that the temperature is 30-60 DEG C, and ensures that the activity of the bacteriophage is not lost. The bacteriophage has a good lysis effect on clostridium perfringens, is strong in infection ability, can infect more host cells with a very small amount of viruses, can effectively lyse A-type and G-type hosts, and can replace antibiotics to resist corrosion of gastric acid, so that intestinal diseases of the hosts are effectively treated.

The invention belongs to the technical field of magnetic control micro-robots and intelligent control, and relates to a mudskipper-imitating magnetic control micro-robot and a control method thereof.The mudskipper-imitating magnetic control micro-robot system comprises a robot body and a control part, and the robot body is composed of two magnetic driving sub-modules and an energy storage module; the two magnetic driving sub-modules are symmetrically fixed at two ends of the energy storage module at a preset interval, and the energy storage module is used for realizing non-magnetic connection of the two magnetic driving sub-modules; the control part comprises a magnetic field generation module for forming a driving magnetic field around the robot body and a controller for adjusting the magnetic field generation module to change the magnetic field intensity and direction so as to drive the robot body to realize jumping motion; the robot designed by the invention can adapt to large deformation of intestinal peristalsis, efficiently cross mucous membrane wrinkles, adapt to unstructured characteristics of intestinal tracts, and can accurately reach a focus area to provide a path for accurate diagnosis and treatment of intestinal diseases.

A polypeptide for repairing a skin wound or a mucosal injury, having obvious effects of alleviating the pathological development of acute and chronic gastrointestinal diseases, promoting repair of a skin wound or a mucosal injury, treating tumors, etc.; and use of the polypeptide in repairing a skin wound or a mucosal injury. By blocking or activating FGF / FGFR1 signaling, the polypeptide capable of binding to an FGFR1 receptor is capable of inhibiting or promoting cell proliferation, vascular hyperplasia, collagen formation, etc.

To provide an intestinal disorder controlling agent, an antiallergic agent, an immunopotentiator and an intestinal adhesion improver of lactic acid bacteria, safely ingestible, inexpensively available and excellent in intestinal adhesion improving action of lactic acid bacteria.SOLUTION: The agent of the present invention contains a flower extract. The flower is a flower of Lythraceae, Asteraceae, Fabaceae, Rosaceae or Iridaceae, and is particularly preferably at least one selected from the group consisting of safflower, pomegranate, kudzu, cherry, chrysanthemum, saffron, peach and rose.SELECTED DRAWING: Figure 1

Provided is a method of treating a disorder mediated by claudin-2 and / or claudin-15, particularly an intestinal disorder, such as colitis or enteritis. The method comprises administering to the subject an effective amount of a compound of formula (I), formula (II), or otherwise as described herein or a pharmaceutically acceptable salt thereof. In another aspect, also provided are compounds of formula (Ia) and pharmaceutically acceptable salts thereof.

The present invention relates to the technical field of traditional Chinese medicine polysaccharides, and particularly relates to a Glehnia littoralis polysaccharide, a preparation method thereof, and an application thereof in the preparation of products for preventing and treating ulcerative colitis. The Glehnia littoralis polysaccharide provided by the present invention is a polysaccharide mixture, and its hydrolyzed monosaccharides include galacturonic acid, L-rhamnose, D-glucose, D-galactose, and L-arabinose. Through experimental verification, the Glehnia littoralis polysaccharide can treat DSS-induced ulcerative colitis in rats, has the potential to treat human ulcerative colitis, and regulate intestinal disorders, and is expected to be developed into a polysaccharide drug for preventing and treating ulcerative colitis.

To provide an apparatus for treating a patient suffering from a disorder related to the passageway of the patient's intestines, such as constipation or incontinence.SOLUTION: An apparatus for treatment includes a pump to be implanted in a patient, where the pump is operable on at least one selected portion of the intestines to pump intestinal contents through the passageway of the intestines. The pump includes a constriction device adapted to alternately constrict the selected portion to at least substantially reduce the volume of the passageway of the intestines along the selected portion and release the selected portion to increase the volume of the passageway of the intestines along the selected portion, so that the intestinal contents are displaced through the passageway of the intestines.SELECTED DRAWING: Figure 2A

A composite bacterial agent, and an application thereof. The composite bacterial agent includes Bifidobacterium longum, Enterococcus faecalis, Enterococcus faecium, Ligilactobacillus animalis, and Companilactobacillus muruki, and provides significant effect in treating intestinal disorders and inflammatory bowel disease in felines caused by bacteria.

The invention particularly discloses a feeding system for adjusting the amount of cecropin AD antibacterial peptide based on the activity state of mutton sheep, and relates to the technical field of mutton sheep breeding. The system comprises a visual monitoring module, a feeding strategy generation module, a feeding action structure module and a data management upper computer module. The visual monitoring module collects and processes mutton sheep activity data through a high-definition camera, an edge computing node and a central data server; the feeding strategy generation module adopts a three-level decision-making framework, evaluates risks by integrating multi-source data, and generates an antibacterial peptide regulation strategy; the feeding action structure module completes mixing and feeding of feed and antibacterial peptide ingredients through cooperation of all components according to a strategy; and the data management upper computer module is responsible for storing system data and realizing data interaction and safety guarantee through a feeding display interface and event alarm display. According to the system, non-inductive monitoring and accurate feeding of the mutton sheep are achieved, the intestinal diseases of the mutton sheep can be effectively prevented, the breeding benefits are improved, and resource waste and potential health risks are reduced.

This invention belongs to the technical field of medical auxiliary equipment, and in particular, relates to a method and apparatus for detecting colon polyps based on endoscopic images. The method comprises the following steps: S1, multi-scale feature extraction based on dilated convolution and a ResNet50 residual network; S2, feature enhancement using frame-assisted contrast learning; S3, prediction based on a CenterNet network; and S4, self-guided bounding box matching during the testing phase. By deploying this efficient detection method on a colonoscopy detection device, the present invention enables real-time and accurate localization of colonoscopic polyps during colonoscopy procedures, improving the efficiency of colonoscopic polyp examination and treatment, reducing the risks associated with multiple examinations and delayed treatment for patients, and providing a strong guarantee for the early diagnosis and treatment of intestinal diseases.

The invention belongs to the technical field of microorganisms, and discloses a clostridium perfringens bacteriophage CP-XHX1 and application thereof, the bacteriophage is preserved in the China Center for Type Culture Collection (CCTCC) on June 17, 2024, and the preservation number is CCTCC NO: M 20241270. The invention also provides a bactericide product prepared from the bacteriophage. The cracking rate of the clostridium perfringens A, E and G reaches 100%, the toxic and side effects are small, and the safety is high. The bacteriophage has a good lysis effect on clostridium perfringens, is strong in infection ability, can infect more host cells with a very small amount of viruses, and can replace antibiotics, so that the intestinal diseases of hosts are effectively treated.

The present invention relates to a method for classifying intestinal diseases based on dual-model dynamic feature fusion. A network based on ResNet and Transformer is constructed to extract features from intestinal lesion images and obtain feature maps of different scales. A bidirectional collaborative depth fusion module is set up in conjunction with ResNet and Transformer to fuse the feature maps in a scale-by-scale collaborative manner. Finally, the output feature map is fused by a dynamic channel attention module, and the fused feature map is output to a dynamic gated feed-forward network to obtain the classification result of intestinal diseases. The present invention improves the feature extraction ability and classification performance of the entire network, can better adapt to different types of intestinal images, and gives accurate diagnostic results; the network can adaptively focus on the features that are most critical to the current task, thereby improving the generalization ability of the model and the accuracy of classification.

The invention discloses a culture method of horse colonic epithelial cells. Belongs to the technical field of cell separation culture. According to the method, the horse colonic epithelial cell model is established in vitro by adopting the colonic tissue of the large monogastric herbivorous animal horse for the first time, the method is simple and convenient in procedure and low in cost, the influence of in-vivo complex environment, specific research conditions and treatment on the cell growth state can be avoided, the influence caused by individual differences is avoided, and the method is suitable for large-scale popularization and application. Meanwhile, impurity cells generated in the separation culture process can be effectively removed, so that the separation efficiency of the colonic epithelial cells is improved. The establishment of the in-vitro model of the colon epithelial cells of the horses can provide a basis for the subsequent research on intestinal diseases. Compared with an enzyme digestion method, the method disclosed by the invention has the advantages that the primary cells can reach about 80% after being cultured for 13 days, and passage operation can be carried out.

This invention relates to an orally administrated nutritional supplement for the management of symptoms of irritable bowel syndrome (IBS) and related functional disorders. The composition includes:1) zinc-L-carnosine 60-100 mg per daily dose or an equivalent combination of zinc and L-carnosine providing 16?20 mg elemental Zn and 55-60 mg L-carnosine; 2) extract of Boswellia serrata resin with 25-35% total AKBA yielding 60-90 mg AKBA; 3) a probiotic blend 30-100 billion CFU that includes, at least, one strain from the genera Streptococcus, Bifidobacterium, and Lactobacillus. The active ingredients are incorporated into an acid-resistant or slow-release pharmaceutical form which limits their release in gastric pH and releases them when the pH is "greater than or equal to" 5.5, ensuring their integrity until they reach the intestine. The combination of the three above components strengthens the intestinal barrier, reduces intestinal inflammation, and restores the intestinal microbiota, providing comprehensive support to patients with IBS and related functional intestinal disorders.

This invention discloses the application of Jerusalem artichoke polysaccharide in the preparation of drugs for regulating intestinal flora, belonging to the field of intestinal flora drugs. The drugs for regulating intestinal flora use Jerusalem artichoke polysaccharide as the active ingredient. These drugs improve intestinal disorders by increasing the proliferation of beneficial intestinal bacteria and the content of short-chain fatty acids, metabolites of intestinal flora. The Jerusalem artichoke polysaccharide prepared by this invention contains uronic acid and pyranose, and is mainly composed of fructose and glucose, with an average molecular weight of 2228 Da. The preparation method of Jerusalem artichoke polysaccharide in this invention has high yield, low cost, and is suitable for industrial production.

The application provides a preparation method and application of a gastrointestinal microenvironment responsive nano-coated probiotic, so as to improve the bioavailability of the probiotic and realize the purpose of synergistically treating intestinal diseases by combining with a therapeutic drug. The gastrointestinal microenvironment responsive nano-coated probiotic is a seaweed salt which forms a coating on the surface of a single probiotic by chelating with calcium ions, and can also coat small molecule anti-inflammatory drugs to protect the probiotic from the gastric environment. When reaching the intestinal neutral environment, the coating is dissolved, and the inhibited probiotic and therapeutic drug are synchronously released. The probiotic inhibits the growth of pathogenic bacteria, maintains the intestinal flora, and maintains the balance of the intestinal flora; meanwhile, the anti-inflammatory effect of the drug is combined, so that the effect of synergistically treating intestinal diseases is achieved.

The invention discloses an intestinal disease detection device based on a tapering multimode fiber ring laser. According to the device, a tapering multimode fiber is prepared through a tapering multimode fiber preparation module by adopting a fused biconical taper method; functional modification is performed on the surface of an optical fiber taper region of the tapering multimode optical fiber through a tapering multimode optical fiber functional module, and a specific antibody of an intestinal disease marker is fixed; an intestinal disease marker detection module is integrated in an optical fiber ring laser system by utilizing a functionalized sensing probe, the laser wavelength drift distance is detected through the optical fiber ring laser system, an intestinal disease marker is detected according to the laser wavelength drift distance, and an intestinal disease detection result is obtained. The spectral line width can be effectively compressed, and the signal-to-noise ratio is improved, so that high-precision, high-sensitivity and rapid label-free detection of the intestinal disease marker is realized.

The invention discloses a feed for relieving intestinal problems under a cold stimulation condition and a preparation method thereof, and belongs to the technical field of broiler feeds, the feed comprises the following components: corn, soybean meal, corn protein powder, sodium chloride, a rutin additive, stone powder, soybean oil and a compound premix, and the feed is used for solving the problems of intestinal disorder and growth performance reduction of broilers under a low temperature condition.

The invention belongs to the technical field of microorganisms, and discloses a clostridium perfringens bacteriophage CP-XHX2 and application thereof, the bacteriophage is preserved in the China Center for Type Culture Collection (CCTCC) on June 17, 2024, and the preservation number is CCTCC NO: M 20241271. The invention also provides a bactericide product prepared from the bacteriophage. The cracking rate of the selected A type clostridium perfringens and D type clostridium perfringens reaches 100%, the toxic and side effects are small, and the safety is high. The bacteriophage has a good lysis effect on clostridium perfringens, is strong in infection ability, can infect more host cells with a very small amount of viruses, and can replace antibiotics, so that the intestinal diseases of hosts are effectively treated.

The present invention relates to a non-invasive method for the diagnosis, prediction, risk stratification and treatment management of intestinal disorders in patients, wherein gases formed by intestinal bacteria in the exhaled gas are assayed; in particular, it relates to a pretest and the stratification of a patient.

The invention relates to the field of biomedicine, in particular to a BON sensitized cell model as well as a preparation method and application thereof. The invention provides an application of a BON sensitized cell model, which is characterized in that paeoniflorin is used for intervening the BON sensitized cell model, and a small molecule target of paeoniflorin is screened by a chemical proteome method of a limited enzyme digestion method; the problems that an existing BON cell line model is not sensitized or sensitization operation is complex, sensitization sensitivity is low, and stability and specificity are poor are solved. The BON-1 cells are treated with isovaleric acid, the sensitization state in intestinal diseases is simulated, and a reliable cell model is provided and can be used for studying the intestinal diseases; isovaleric acid and paeoniflorin have a synergistic effect, so that compared with unsensitized cells, the sensitivity and the specificity are higher; target screening is carried out by adopting a novel chemical proteomics method of coupling a limited enzyme digestion method with a mass spectrum (LiP-MS) technology, chemical probe preparation is not needed, and the method has the characteristics that the operation is simple and convenient, and a target sequence can be finely positioned.

This document describes the use of the CRB1 gene in the preparation of drugs for treating systemic diseases such as eye and intestinal disorders. It also describes the use of CRB1 gene-based therapeutics in the preparation of drugs for treating systemic diseases such as eye and intestinal disorders.

The present disclosure relates to a wet food composition for a companion animal having an intestinal disorder, the wet food composition comprising, in dry matter: (a) from about 15% to about 45% by weight of a protein; (b) from about 5% to about 25% by weight fat; and (c) from about 6% to about 14% by weight of total dietary fibers (TDF); wherein at least about 50% by weight of the total amount of TDF is derived from semen plantaginis on a dry matter basis.

The invention relates to the technical field of medical instruments, in particular to a fixed microbubble tracing intestinal juice sampling capsule which comprises an enteric shell, a silica gel main body shell, a pH response dissolving plug, a vacuum sampling cavity, a hydrogel self-sealing ring and a fixed microbubble tracing layer. The enteric shell covers the outer side of the silica gel main body shell, the pH response dissolving plug is embedded in a sampling opening of the silica gel main body shell, the vacuum sampling cavity is formed in the silica gel main body shell, and the hydrogel self-sealing ring surrounds the opening edge of the vacuum sampling cavity; ultrasonic real-time tracking is achieved through the fixed microbubble tracing layer, so that if the capsule is not discharged in the later period, real-time positioning can be achieved, the sample purity exceeds 96%, the sampling success rate is far higher than that of an existing capsule, the built-in stabilizer keeps the biological activity of the sample, a high-quality sample is provided for precise diagnosis of intestinal diseases and microbiome research, and the application prospect is wide. Compared with the prior art, the diagnosis accuracy is improved by more than 30%.

Where an implanted reservoir for intestinal contents is formed from surgically modified intestine that has been cut along a mutual contact line of laterally adjacent sections of a bent portion of intestine and connected so that the resulting upper and lower halves of the intestine form an intestinal wall of the reservoir, the system for emptying such intestinal reservoir comprises an artificial flow control device implantable in the patient's body and adapted to control flow of the intestinal contents from said reservoir, the flow control device comprising at least one pump adapted to act on said intestinal wall so as to reduce the reservoir's volume, thereby emptying the reservoir. The system may further comprise an entry valve upstream of the reservoir and an exit valve downstream from the reservoir. The pump may be an electrical stimulation type pump, a hydraulically acting type pump or / and a mechanically acting type pump.

The application belongs to the technical field of microorganisms, and discloses a heat-resistant and acid-alkali-resistant Clostridium perfringens bacteriophage XHX-CP-18P and application thereof, the bacteriophage is preserved in the China Center for Type Culture Collection (CCTCC) on March 17, 2025, and the preservation number is CCTCC NO: M 2025492. The application also provides a bactericide product prepared from the bacteriophage. The bacteriophage has good acid-alkali resistance under the condition that pH is 3-13, and has heat resistance under the condition that temperature is 30-60 DEG C, so that the activity of the bacteriophage is ensured not to be lost. The bacteriophage has good lysis effect on Clostridium perfringens, has strong infection capacity, can infect more host cells with very small virus amount, and can effectively lyse A type and G type hosts, so that the bacteriophage can replace antibiotics, resist corrosion of gastric acid, and effectively treat host intestinal diseases.